Medivir 2023 Annual Report Published

Author:

Medivir AB has released its Annual Report for 2023, which is now available on the company’s website. The report highlights the progress made in the ongoing phase 1b/2a study of Medivir’s lead project, fostrox, in combination with Lenvima® for the treatment of advanced primary liver cancer.

The study has shown promising results, with continued improvement in clinical benefit for patients. Data presented at the ASCO-GI conference in January 2024 demonstrated further increases in the proportion of patients experiencing a reduction in liver tumors and prolonged treatment with halted tumor growth. The impressive data has garnered significant interest and has continued to improve in the first quarter of 2024.

The positive clinical outcomes and high medical need for an effective treatment present an opportunity for Medivir to accelerate the clinical development of fostrox. The company aims to become the first approved pharmaceutical therapy for the second-line treatment of liver cancer, a market valued at approximately $2.5 billion annually. Medivir is fully focused on advancing fostrox towards potential accelerated approval and is also planning for the initiation of clinical trials for other projects in partnership with licensed partners in 2024.

Medivir is dedicated to developing innovative drugs for cancer, particularly areas where current therapies are limited or non-existent. The company’s focus is on fostrox, a pro-drug designed to selectively treat liver cancer while minimizing side effects. Collaboration and partnerships are integral to Medivir’s business model, with both in-house and partnered drug development initiatives.

For more information, the Medivir Annual Report 2023 can be accessed on the company’s website. Contact information for further inquiries is provided in the press release.

Medivir AB operates in the pharmaceutical industry, specifically focusing on the development of innovative drugs for cancer treatment. The company is dedicated to addressing unmet medical needs in areas where current therapies are limited or non-existent.

In particular, Medivir’s lead project is fostrox, a pro-drug designed to selectively treat liver cancer while minimizing side effects. Liver cancer is a significant medical need, and there is high demand for an effective treatment option in the second-line setting. Medivir aims to become the first approved pharmaceutical therapy for the second-line treatment of liver cancer, which is a market valued at approximately $2.5 billion annually.

The positive clinical outcomes observed in the phase 1b/2a study of fostrox, in combination with Lenvima®, for the treatment of advanced primary liver cancer have garnered significant interest. Data presented at the ASCO-GI conference in January 2024 demonstrated promising results, including reductions in liver tumors and prolonged treatment with halted tumor growth. These results have continued to improve in the first quarter of 2024, further highlighting the potential of fostrox.

With these encouraging results, Medivir is focused on accelerating the clinical development of fostrox. The company is actively working towards potential accelerated approval and is planning to initiate clinical trials for other projects in partnership with licensed partners in 2024.

Medivir’s business model emphasizes collaboration and partnerships. The company engages in both in-house and partnered drug development initiatives, recognizing the importance of working with other organizations to advance its pipeline.

For more information, the Medivir Annual Report 2023 can be accessed on the company’s website. This report provides a comprehensive overview of Medivir’s achievements, progress, and future plans. Interested parties can visit the company’s website for further information and can reach out to the provided contact information for inquiries.